Vigabatrin visual toxicity: Evolution and dose dependence

Epilepsia

Volumn 42, Issue 5, 2001, Pages 609-615

  Malmgren, Kristina ^a   Ben Menachem, Elinor ^a   Frisén, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti epileptic drugs; Dose dependence; Vigabatrin; Visual field defects

Indexed keywords

VIGABATRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; EPILEPSY; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; PERIMETRY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; VISUAL FIELD; VISUAL FIELD DEFECT;

ADULT; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERIMETRY; PROGNOSIS; RETINA; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 0035023677     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2001.28600.x     Document Type: Article

References (27)

1. Ben-Menachem E, Persson LI, Schlechter PJ, et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989; 27:79S-85S.
2. Loscher W. Effect of inhibitors of GABA in brain tissue and synoptosomal fractions. J Neurochem 1981;36:1521-7.
3. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989;27(suppl 1):43S-5S.
4. Gibson JP, Yarington JT, Loudy DB, et al. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-38.
5. Sussman NM, Weiss KI, Schroeder CE. Vigabatrin: effect on in vivo and ex vivo magnetic resonance imaging of dog brains [Abstract]. Epilepsia 1991;31(suppl 1):13.
6. Jackson GD, Grunevald RA, Connely A, et al. Quantitative MR relaxometry study of effects of vigabatrin on the brains of patients with epilepsy. Epilepsy Res 1994;18:127-37.
7. Pedersen B, Hojgaard K, Dam M. Vigabatrin: no microvacuoles in a human brain. Epilepsy Res 1987;1:74-6.
8. Sivenius J, Paljarvi L, Vapalahti M, et al. Vigabatrin (gamma-vinyl-GABA): neuropathologic evaluation in five patients. Epilepsia 1993;34:193-6.
9. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-1.
10. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-8.
11. Mackenzie R, Klistoner A. Severe persistent visual field constriction associated with vigabatrin: asymptomatic as well as symptomatic defects occur with vigabatrin. BMJ 1998;316:233.
12. Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:922-6.
13. Vanhatalo S, Pääkkonen L. Visual field constriction in children treated with vigabatrin. Neurology 1999;52:1713-4.
14. Hardus P, Verduin WM, Postma G, et al. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 2000; 41:581-7.
15. Zackon DH, Racette L, Daneshvar H, et al. Visual field loss associated with vigabatrin. Invest Ophthalmol Vis Sci 1999;40:S565.
16. Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin treatment. J Neurol Neurosurg Psychiatry 1999; 67:716-22.
17. Egge K. The visual field in normal subjects. Acta Ophthalmol 1984;169(suppl):1-64.
18. Lorenz R, Kuck H. Visuelle Störungen durch Diphenylhydantoin: klinische und elektroophthalmologische Befunde. Klin Monatsbl Augenheilkd 1988;192:244-7.
19. Elder MJ. Diazepam and its effects on visual fields. Aust N Z J Ophthalmol 1992;20:267-70.
20. Wohlrab G, Boltshauser E, Schmitt B, et al. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 1999;30:130-2.
21. Baulac M, Normann JP, Lanoe Y. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents. Lancet 1998;15:546.
22. Arndt CF, Derambure P, Defoort S, et al. Is visual impairment related to vigabatrin reversible? Epilepsia 1999:40(suppl 2):256.
23. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999;53:2082-7.
24. Cunha-Vaz JG. The blood-ocular barriers: past, present and future. Doc Ophthalmol 1997;93:149-57.
25. Wild JM, Martinez C, Reinshagen G, et al. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40:1784-94.
26. Frisén L. Clinical tests of vision. New York: Raven Press, 1990.
27. Frisén L. High-pass resolution perimetry: a clinical review. Doc Ophthalmol 1996;83:1-25.